CAMP4 Therapeutics(CAMP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
CAMP4 Therapeutics
CAMP.US
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc.
1.876 T
CAMP.USMarket value -Rank by Market Cap -/-

Financial Score

19/06/2026 Update
D
BiotechnologyIndustry
Industry Ranking256/389
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-209.28%E
    • Profit Margin-2193.72%E
    • Gross Margin-685.16%E
  • Growth ScoreB
    • Revenue YoY160.53%A
    • Net Profit YoY-66.69%E
    • Total Assets YoY68.00%A
    • Net Assets YoY-40.08%E
  • Cash ScoreB
    • Cash Flow Margin30.41%D
    • OCF YoY160.53%A
  • Operating ScoreE
    • Turnover0.05E
  • Debt ScoreD
    • Gearing Ratio70.70%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    benzinga_article·
    US
    YDES
    -3.97%
    US
    HITI
    -2.53%
    US
    PRFX
    -10.81%
    benzinga_article·
    US
    YDES
    -3.97%
    US
    HITI
    -2.53%
    US
    PRFX
    -10.81%

    This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

    benzinga_article·
    US
    CAMP
    -0.24%
    US
    XOM
    -2.08%
    US
    EXR
    +0.98%
    benzinga_article·
    US
    CAMP
    -0.24%
    US
    XOM
    -2.08%
    US
    EXR
    +0.98%

    Camp4 Therapeutics shares are trading higher after Chardan Capital initiated coverage on the stock with a Buy rating and announced a $6.5 price target.

    benzinga_article·
    US
    CAMP
    -0.24%
    benzinga_article·
    US
    CAMP
    -0.24%

    CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital

    Tip Ranks·
    US
    CAMP
    -0.24%
    Tip Ranks·
    US
    CAMP
    -0.24%

    CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

    Tip Ranks·
    US
    CAMP
    -0.24%
    US
    BIB
    +0.08%
    US
    XBI
    +0.95%
    Tip Ranks·
    US
    CAMP
    -0.24%
    US
    BIB
    +0.08%
    US
    XBI
    +0.95%
    © 2026 Longbridge｜Disclaimer